{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:37:32Z","timestamp":1791067052813,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s40266-018-0602-y","type":"journal-article","created":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T07:58:27Z","timestamp":1541059107000},"page":"1109-1117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Safety, Tolerability and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy in Patients Aged\u2009\u2265\u200965\u00a0Years with Focal Seizures"],"prefix":"10.1007","volume":"35","author":[{"given":"Raquel","family":"Costa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Steinhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Gama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1bio","family":"Ikedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9-Francisco","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcio","family":"Soares-da-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,1]]},"reference":[{"key":"602_CR1","unstructured":"CHMP\/EWP\/566\/98 rev 2, Committee for medicinal products for human use. Guideline on clinical investigation of medicinal products in the treatment of epileptic disorders. July 2\n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/01\/WC500070043.pdf\n                    \n                  . Accessed 25 Sept 2018."},{"key":"602_CR2","unstructured":"CPMP\/ICH\/379\/95, International Conference of Harmonisation (ICH) E7. Studies in Support of Special Populations: Geriatrics. 1994. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500002875.pdf\n                    \n                  . Accessed 25 Sept 2018."},{"issue":"11","key":"602_CR3","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s11910-016-0696-8","volume":"16","author":"PV Motika","year":"2016","unstructured":"Motika PV, Spencer DC. Treatment of epilepsy in the elderly. Curr Neurol Neurosci Rep. 2016;16(11):96.","journal-title":"Curr Neurol Neurosci Rep."},{"issue":"1","key":"602_CR4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.nurt.2006.10.005","volume":"4","author":"L Almeida","year":"2007","unstructured":"Almeida L, Soares da Silva P. Eslicarbazepine acetate (BIA 2-093). Neurotherapeutics. 2007;4(1):88\u201396.","journal-title":"Neurotherapeutics"},{"issue":"5","key":"602_CR5","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1046\/j.1528-1157.2001.43600.x","volume":"42","author":"MJ Bonifacio","year":"2001","unstructured":"Bonifacio MJ, Sheridan RD, Parada A, Cunha RA, Patmore L, Soares da Silva P. Interaction of the novel anticonvulsant, BIA 2 093, with voltage-gated sodium channels: comparison with carbamazepine. Epilepsia. 2001;42(5):600\u20138.","journal-title":"Epilepsia"},{"issue":"5","key":"602_CR6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/bdd.549","volume":"28","author":"A Falc\u00e3o","year":"2007","unstructured":"Falc\u00e3o A, Maia J, Almeida L, Mazur D, Gellert M, Soares da Silva P. Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2 093), a new voltage gated sodium channel blocker. Biopharm Drug Dispos. 2007;28(5):249\u201356.","journal-title":"Biopharm Drug Dispos"},{"issue":"9","key":"602_CR7","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1177\/0091270005279364","volume":"45","author":"L Almeida","year":"2005","unstructured":"Almeida L, Falc\u00e3o A, Maia J, Mazur D, Gellert M, Soares da Silva P. Single dose and steady state pharmacokinetics of eslicarbazepine acetate (BIA 2 093) in healthy elderly and young subjects. J Clin Pharmacol. 2005;45(9):1062\u20136.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"602_CR8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.5414\/CPP46119","volume":"46","author":"J Maia","year":"2008","unstructured":"Maia J, Almeida L, Falc\u00e3o A, et al. Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. Int J Clin Pharmacol Ther. 2008;46(3):119\u201330.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"4","key":"602_CR9","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2165\/00126839-200506040-00002","volume":"6","author":"J Maia","year":"2005","unstructured":"Maia J, Vaz da Silva M, Almeida L, et al. Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2 093). Drugs R.D. 2005;6(4):201\u20136.","journal-title":"Drugs R.D."},{"issue":"3","key":"602_CR10","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00228-007-0414-1","volume":"64","author":"L Almeida","year":"2008","unstructured":"Almeida L, Potgieter JH, Maia J, Potgieter MA, Mota F, Soares-da-Silva P. Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur J Clin Pharmacol. 2008;64(3):267\u201373.","journal-title":"Eur J Clin Pharmacol."},{"issue":"21","key":"602_CR11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/0028-3908(71)90039-6","volume":"10","author":"H Norris","year":"1971","unstructured":"Norris H. The action of sedatives on brain stem oculomotor systems in man. Neuropharmacology. 1971;10(21):181\u201391.","journal-title":"Neuropharmacology"},{"key":"602_CR12","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.eplepsyres.2010.01.014","volume":"89","author":"E Ben-Menachem","year":"2010","unstructured":"Ben-Menachem E, Gabbai AA, Hufnagel A, Maia J, Almeida L, Soares-da-Silva P. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res. 2010;89:278\u201385.","journal-title":"Epilepsy Res."},{"key":"602_CR13","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/j.1528-1167.2008.01946.x","volume":"50","author":"C Elger","year":"2009","unstructured":"Elger C, Halasz P, Maia J, Almeida L, Soares-da-Silva P. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia. 2009;50:454\u201363.","journal-title":"Epilepsia"},{"key":"602_CR14","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/epi.12894","volume":"56","author":"MR Sperling","year":"2015","unstructured":"Sperling MR, Abou-Khalil B, Harvey J, et al. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: results of a phase III, double-blind, randomized, placebo-controlled trial. Epilepsia. 2015;56:244\u201353.","journal-title":"Epilepsia"},{"key":"602_CR15","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1600-0404.2009.01218.x","volume":"120","author":"A Gil-Nagel","year":"2009","unstructured":"Gil-Nagel A, Lopes-Lima J, Almeida L, Maia J, Soares-da-Silva P. Efficacy and safety of 800 and 1200\u00a0mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand. 2009;120:281\u20137.","journal-title":"Acta Neurol Scand."},{"issue":"2","key":"602_CR16","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1525-5050(03)00037-4","volume":"4","author":"E Kutluay","year":"2003","unstructured":"Kutluay E, McCague K, D\u2019Souza J, Beydoun A. Safety and tolerability of oxcarbazepine in elderly patients with epilepsy. Epilepsy Behav. 2003;4(2):175\u201380.","journal-title":"Epilepsy Behav."},{"issue":"6","key":"602_CR17","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/ane.12162","volume":"128","author":"E Trinka","year":"2013","unstructured":"Trinka E, Giorgi L, Patten A, Segieth J. Safety and tolerability of zonisamide in elderly patients with epilepsy. Acta Neurol Scand. 2013;128(6):422\u20138.","journal-title":"Acta Neurol Scand."},{"key":"602_CR18","unstructured":"European Medicines Agency. Zebinix (eslicarbazepine acetate): EU summary of product characteristics. 2017. \n                    https:\/\/www.ema.europa.eu\/documents\/product-information\/zebinix-epar-product-information_en.pdf\n                    \n                  . Accessed 29 Sept 2018."},{"issue":"4","key":"602_CR19","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.seizure.2010.12.015","volume":"20","author":"KJ Werhahn","year":"2011","unstructured":"Werhahn KJ, Klimpe S, Balkaya S, Trinka E, Kr\u00e4mer G. The safety and efficacy of add-on levetiracetam in elderly patients with focal epilepsy: a one-year observational study. Seizure. 2011;20(4):305\u201311.","journal-title":"Seizure."},{"key":"602_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.seizure.2017.04.003","volume":"48","author":"A G\u00f3mez-Ib\u00e1\u00f1ez","year":"2017","unstructured":"G\u00f3mez-Ib\u00e1\u00f1ez A, Serratosa JM, Guillam\u00f3n E, et al. Efficacy and safety of eslicarbazepine-acetate in elderly patients with focal epilepsy: Case series. Seizure. 2017;48:53\u20136.","journal-title":"Seizure."},{"key":"602_CR21","first-page":"1","volume":"44","author":"RE Ramsay","year":"2003","unstructured":"Ramsay RE. Zonisamide (ZNS, Zonegran (R)): efficacy and safety stratified by patient age, p292. abstracts from the 25th international epilepsy congress Lisbon, Portugal October 12\u201316, 2003. Epilepsia. 2003;44:1\u2013223.","journal-title":"Epilepsia."}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-018-0602-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-018-0602-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-018-0602-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T10:33:07Z","timestamp":1572604387000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-018-0602-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,1]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["602"],"URL":"https:\/\/doi.org\/10.1007\/s40266-018-0602-y","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,1]]},"assertion":[{"value":"1 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was sponsored by BIAL-Portela & C\u00aa, S.A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors were involved in the design or conduct of the study, the collection, management or analysis of the data, and the preparation or review of the manuscript. Drs Costa, Gama, Ikedo, Rocha and Soares-da-Silva are or were employees of BIAL at the time of the study. Dr Steinhoff has no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by national Independent Ethics Committee and Competent Authorities. The study was conducted according to the Helsinki Declaration, ICH Good Clinical Practice recommendations and applicable local regulations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was received from all subjects prior to the conduct of any trial-related procedures.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}